GRGranules India532482Quarterly results

Board approves Sept-quarter results with unmodified auditor review; warrants converted into equity

Board approved unaudited standalone and consolidated results for the quarter and half year ended Sep 30, 2026, after Audit Committee review.

By ScoutQuest · Mon 2 Nov 2026, 4:52 PM IST · 2 min read

Consolidated Revenue from Operations (Rs mn)

15,599.74 (vs 12,969.88)

Consolidated Profit for the Period (Rs mn)

1,818.37 (vs 1,306.06)

Warrants Converted into Equity Shares

24,982,906 warrants converted into equity shares, balance subscription paid

The Board of Directors of Granules India met on November 02, 2026 and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The Audit Committee reviewed the results before the Board approved them, and the statutory auditors, S.R. Batliboi & Associates LLP, issued limited review reports on both sets of statements.

Auditor's review conclusion

Both review reports are unmodified. The auditors state that nothing has come to their attention that causes them to believe the statements contain any material misstatement or fail to disclose what the listing rules require. A limited review is narrower than a full audit, so it gives moderate assurance rather than an audit opinion.

Consolidated results, quarter ended September 30, 2026 (figures in Rs millions)

• Revenue from operations: 15,599.74, against 12,969.88 in the same quarter a year earlier.
• Profit for the period: 1,818.37, against 1,306.06 a year earlier.

Both the revenue line and the profit line were higher year on year at the consolidated level, which includes the group's subsidiaries.

Standalone results, quarter ended September 30, 2026 (figures in Rs millions)

• Revenue from operations: 9,478.21.
• Profit for the period: 1,085.16, against 1,206.13 a year earlier.

So on a standalone basis, profit for the period was lower than the year-earlier figure.

Warrants converted into equity shares

During the quarter and half year ended September 30, 2026, holders of 24,982,906 warrants exercised the right to convert them into equity shares and paid the balance subscription amount. The company allotted equity shares of face value Re. 1 each on that conversion. The effect is a larger number of equity shares in issue and receipt of the remaining subscription money.

Other points from the notes

• The Gagillapur facility had received a USFDA warning letter in February 2025 following an inspection conducted during August-September 2024. In a later inspection, the USFDA concluded with the issuance of a Form FDA 483, with no observations relating to data integrity or cross-contamination. The company is responding within the stipulated timelines and expects no impact on manufacturing or distribution from the facility.
• Wholly owned subsidiaries were incorporated in Brazil (Triton Farmaceutica Do Brasil LTDA) and in Mexico (Triton Farmaceutica S.A. de C.V).
• The company operates in one reportable business segment: pharmaceutical products, including ingredients and intermediates.

What a retail investor can take away

This is a routine quarterly results disclosure. The points worth reading closely are the year-on-year direction of consolidated Revenue from operations and Profit for the period, the standalone trend where profit for the period was lower, the unmodified review conclusion, and the increase in the number of equity shares after the warrant conversion.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev